Loading...
01/11 11:06
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company's earnings call reveals mixed results: a positive diversification strategy and an improved gross margin, but significant risks include an EPS miss, declining transportation sales, and a weak book-to-bill ratio. The Q&A section highlights concerns about tariffs and unclear timelines for product ramp-up. The lowered revenue guidance further contributes to a negative outlook, likely resulting in a stock price decline of 2% to 8%.
EPS $0.4471 EPS, down from expectations of $0.59.
Sales (Q4 2024) $127 million, up 2% from Q4 2023.
Sales (Full Year 2024) $516 million, down 6% from 2023.
Diversified End Market Sales (Q4 2024) Up 28% compared to Q4 2023.
Transportation Sales (Q4 2024) Down 18% compared to Q4 2023.
Book-to-Bill Ratio (Q4 2024) 0.96, unchanged from Q4 2023.
Adjusted Gross Margin (Full Year 2024) Up 243 basis points from 2023.
Electrification Wins: We had six wins in electrification from our portfolio of existing powertrain agnostic products.
Diversified Market Revenue Contribution: Revenue from our diversified markets accounted for 56% of overall company revenue in the fourth quarter and 51% for the full year 2024.
Sales Performance: For the quarter, diversified end market sales, including sales to medical, aerospace and defense and industrial end markets were up 28%.
Transportation Sales Decline: Transportation sales were down 18% from the same period last year.
Adjusted Gross Margin Improvement: Adjusted gross margin for the full year 2024 was up 243 basis points from 2023.
Diversification Strategy: We continue to execute on our diversification strategy to accelerate growth in our diversified medical, industrial, aerospace and defense markets.
SyQwest Acquisition Impact: We expect further progress in 2025 with a full year of revenue contribution from the SyQwest acquisition.
Earnings Expectations: CTS Corporation reported an EPS of $0.4471, missing the expectations of $0.59, indicating potential challenges in meeting financial targets.
Macroeconomic Challenges: The company is driving revenue growth in a challenging macroeconomic backdrop, suggesting risks related to economic conditions affecting sales.
Sales Decline in Transportation: Transportation sales were down 18% from the same period last year, highlighting a significant risk in this segment of the business.
Overall Sales Decline: For the full year, sales were $516 million, down 6% from 2023, indicating a broader risk of declining revenue.
Book-to-Bill Ratio: The book-to-bill ratio for the fourth quarter remained at 0.96, which is below 1, suggesting potential future revenue challenges.
Diversification Strategy: CTS Corporation continues to execute on its diversification strategy to accelerate growth in diversified medical, industrial, aerospace, and defense markets.
Electrification Wins: The company reported six wins in electrification from its portfolio of existing powertrain agnostic products.
SyQwest Acquisition: CTS expects further progress in 2025 with a full year of revenue contribution from the SyQwest acquisition.
Quality of Earnings: The strategic focus on diversification has improved the quality of earnings, reflected by an adjusted gross margin increase of 243 basis points from 2023.
Revenue Growth Initiatives: Driving revenue growth through organic initiatives and leveraging a strong balance sheet for appropriate acquisitions remains a priority.
Sales Expectations: For the fourth quarter, CTS reported sales of $127 million, up 2% from Q4 2023, while full year sales were $516 million, down 6% from 2023.
Diversified End Market Sales: Sales to diversified end markets were up 28% in Q4, while transportation sales were down 18%.
Book-to-Bill Ratio: The book-to-bill ratio for Q4 remained at 0.96, similar to Q4 2023.
The selected topic was not discussed during the call.
The earnings call reflects mixed signals: while aerospace, defense, industrial, and medical markets show strong performance, the transportation sector struggles, and EPS guidance was lowered due to tax impacts. Positive aspects include strong market growth and the SyQwest acquisition meeting expectations, but the adverse tax impact and transportation market softness temper enthusiasm. The Q&A session highlighted some concerns, such as unclear management responses and ongoing tax issues. Given the balance of positive and negative factors, the stock price is likely to remain stable over the next two weeks.
The earnings call showed positive financial performance with improved EBITDA and gross margin, strong aerospace and medical sales, and shareholder returns. Despite transportation sales decline, guidance remains optimistic. Analysts' Q&A highlighted growth in therapeutics and potential recovery in transportation. The integration of SyQwest and operational efficiency are progressing well. Overall, the positive financial metrics and optimistic guidance suggest a likely stock price increase in the near term.
The earnings call presents a mixed sentiment. Positive elements include a strong book-to-bill ratio, revenue growth in diversified markets, and shareholder returns via buybacks. However, challenges such as declining transportation sales, geopolitical uncertainties, and a drop in EPS temper optimism. The Q&A session reveals some uncertainties, particularly around tariffs and the China market, but also highlights potential growth in diversified markets. Overall, the sentiment is balanced, leading to a neutral stock price prediction over the next two weeks.
The company's earnings call reveals mixed results: a positive diversification strategy and an improved gross margin, but significant risks include an EPS miss, declining transportation sales, and a weak book-to-bill ratio. The Q&A section highlights concerns about tariffs and unclear timelines for product ramp-up. The lowered revenue guidance further contributes to a negative outlook, likely resulting in a stock price decline of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
